NO319151B1 - Nye, 3-substituerte 3H-2,3-benzodiazepinderivater, fremstilling av dem og anvendelse av dem for fremstilling av legemidler - Google Patents

Nye, 3-substituerte 3H-2,3-benzodiazepinderivater, fremstilling av dem og anvendelse av dem for fremstilling av legemidler Download PDF

Info

Publication number: NO319151B1
Authority: NO; Norway
Prior art keywords: hydrogen; group; compounds; optionally; alkyl
Prior art date: 1994-08-01

Application number

NO19970435A

Other languages

English (en)

Norwegian (no)

Other versions

NO970435L (no

NO970435D0 (no

Inventor

Ferenc Andrasi

Gabor Zolyomi

Istvan Tarnawa

Pal Berzsenyi

Tamas Hamori

Sandor Solyom

Erzsebet Birkas Falglne

Istvan Ling

Tibor Hasko

Gabor Kapus

Emese Csuzdl

Marta Szollosy

Franciska Vldane

Antal Simay

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-01

Filing date

1997-01-31

Publication date

2005-06-27

1997-01-31 Application filed by Schering Ag filed Critical Schering Ag

1997-01-31 Publication of NO970435L publication Critical patent/NO970435L/no

1997-01-31 Publication of NO970435D0 publication Critical patent/NO970435D0/no

2005-06-27 Publication of NO319151B1 publication Critical patent/NO319151B1/no

Links

238000004519 manufacturing process Methods 0.000 title claims abstract description 5
239000003814 drug Substances 0.000 title claims description 10
238000002360 preparation method Methods 0.000 title claims description 6
RQKDTQACQPHOQL-UHFFFAOYSA-N 3h-2,3-benzodiazepine Chemical class C1=NNC=CC2=CC=CC=C21 RQKDTQACQPHOQL-UHFFFAOYSA-N 0.000 title abstract description 4
150000001875 compounds Chemical class 0.000 claims description 56
229910052739 hydrogen Inorganic materials 0.000 claims description 32
239000001257 hydrogen Substances 0.000 claims description 30
150000002431 hydrogen Chemical class 0.000 claims description 20
150000003839 salts Chemical class 0.000 claims description 15
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
229910052736 halogen Inorganic materials 0.000 claims description 13
150000002367 halogens Chemical group 0.000 claims description 13
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
229910052731 fluorine Inorganic materials 0.000 claims description 8
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
238000000034 method Methods 0.000 claims description 7
229910052794 bromium Inorganic materials 0.000 claims description 6
229910052801 chlorine Inorganic materials 0.000 claims description 6
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
229940079593 drug Drugs 0.000 claims description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
230000002829 reductive effect Effects 0.000 claims description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
SSZCVESQZCYBBF-UHFFFAOYSA-N 1-[5-(4-aminophenyl)-8-methyl-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-7-yl]ethanone Chemical group C12=CC=3OCOC=3C=C2C=C(C)N(C(=O)C)N=C1C1=CC=C(N)C=C1 SSZCVESQZCYBBF-UHFFFAOYSA-N 0.000 claims description 4
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
150000001412 amines Chemical class 0.000 claims description 4
239000011737 fluorine Substances 0.000 claims description 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 3
150000001298 alcohols Chemical class 0.000 claims description 3
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
125000004185 ester group Chemical group 0.000 claims description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
239000008177 pharmaceutical agent Substances 0.000 abstract 1
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
238000002844 melting Methods 0.000 description 17
230000008018 melting Effects 0.000 description 17
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 12
238000006722 reduction reaction Methods 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
239000000243 solution Substances 0.000 description 11
238000011282 treatment Methods 0.000 description 9
-1 aromatic mono- Chemical class 0.000 description 8
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
239000002253 acid Substances 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
239000000203 mixture Substances 0.000 description 7
102000003678 AMPA Receptors Human genes 0.000 description 6
108090000078 AMPA Receptors Proteins 0.000 description 6
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
239000000725 suspension Substances 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000000354 decomposition reaction Methods 0.000 description 5
235000019439 ethyl acetate Nutrition 0.000 description 5
210000001525 retina Anatomy 0.000 description 5
239000002904 solvent Substances 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
229940049706 benzodiazepine Drugs 0.000 description 4
239000003480 eluent Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
229910000027 potassium carbonate Inorganic materials 0.000 description 4
239000000047 product Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
ZVHGCRPPOMGSHZ-UHFFFAOYSA-N 1-[8-methyl-5-(4-nitrophenyl)-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-7-yl]ethanone Chemical compound C12=CC=3OCOC=3C=C2C=C(C)N(C(=O)C)N=C1C1=CC=C([N+]([O-])=O)C=C1 ZVHGCRPPOMGSHZ-UHFFFAOYSA-N 0.000 description 3
206010010904 Convulsion Diseases 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
150000008064 anhydrides Chemical class 0.000 description 3
238000009835 boiling Methods 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000036461 convulsion Effects 0.000 description 3
239000012043 crude product Substances 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
239000003257 excitatory amino acid Substances 0.000 description 3
230000002461 excitatory amino acid Effects 0.000 description 3
IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
RNQRLYWVOJJHKD-UHFFFAOYSA-N 8-methyl-5-(4-nitrophenyl)-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepine Chemical compound C12=CC=3OCOC=3C=C2CC(C)=NN=C1C1=CC=C([N+]([O-])=O)C=C1 RNQRLYWVOJJHKD-UHFFFAOYSA-N 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
RPBDCDQMCRHNLM-UHFFFAOYSA-N C1=NNC=C2C=CC=CC2=C1 Chemical compound C1=NNC=C2C=CC=CC2=C1 RPBDCDQMCRHNLM-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
206010053398 Clonic convulsion Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000007868 Raney catalyst Substances 0.000 description 2
229910000564 Raney nickel Inorganic materials 0.000 description 2
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
230000030833 cell death Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N ***e Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
239000012954 diazonium Substances 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
239000008298 dragée Substances 0.000 description 2
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
239000011630 iodine Substances 0.000 description 2
ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
208000020016 psychiatric disease Diseases 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
CQJNQAJVZFDGDS-UHFFFAOYSA-N 1-[12-(4-aminophenyl)-15-methyl-4,7-dioxa-13,14-diazatricyclo[9.5.0.03,9]hexadeca-1(11),2,9,12,15-pentaen-14-yl]ethanone Chemical compound C(C)(=O)N1N=C(C2=C(C=C1C)C=C1C(=C2)COCCO1)C1=CC=C(C=C1)N CQJNQAJVZFDGDS-UHFFFAOYSA-N 0.000 description 1
ZMDPEVLALNINQQ-UHFFFAOYSA-N 1-[15-methyl-12-(4-nitrophenyl)-4,7-dioxa-13,14-diazatricyclo[9.5.0.03,9]hexadeca-1(11),2,9,12,15-pentaen-14-yl]ethanone Chemical compound C12=CC=3COCCOC=3C=C2C=C(C)N(C(=O)C)N=C1C1=CC=C([N+]([O-])=O)C=C1 ZMDPEVLALNINQQ-UHFFFAOYSA-N 0.000 description 1
GJYWKWKWZCUNTJ-UHFFFAOYSA-N 15-methyl-12-(4-nitrophenyl)-4,7-dioxa-13,14-diazatricyclo[9.5.0.03,9]hexadeca-1,3(9),10,12,14-pentaene Chemical compound C12=CC=3COCCOC=3C=C2CC(C)=NN=C1C1=CC=C([N+]([O-])=O)C=C1 GJYWKWKWZCUNTJ-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
QYODITYLKYWQEM-UHFFFAOYSA-N 4-methyl-1-(4-nitrophenyl)-5H-2,3-benzodiazepine-7,8-diol Chemical compound C12=CC(O)=C(O)C=C2CC(C)=NN=C1C1=CC=C([N+]([O-])=O)C=C1 QYODITYLKYWQEM-UHFFFAOYSA-N 0.000 description 1
BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 1
JSLIDTGHSZKNHE-UHFFFAOYSA-N 7-ethyl-5-(4-nitrophenyl)-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isochromene Chemical compound O1C(CC)CC2=CC=3OCOC=3C=C2C1C1=CC=C([N+]([O-])=O)C=C1 JSLIDTGHSZKNHE-UHFFFAOYSA-N 0.000 description 1
DJXIVFHYOLZSBW-UHFFFAOYSA-N 8-methyl-5-(4-nitrophenyl)-8,9-dihydro-7h-[1,3]dioxolo[4,5-h][2,3]benzodiazepine Chemical compound N=1NC(C)CC2=CC=3OCOC=3C=C2C=1C1=CC=C([N+]([O-])=O)C=C1 DJXIVFHYOLZSBW-UHFFFAOYSA-N 0.000 description 1
SDPQMKFQURYHMV-UHFFFAOYSA-N 8-methyl-5-phenyl-9H-[1,3]dioxolo[4,5-h][2,3]benzodiazepine Chemical compound CC1=NN=C(C2=CC=CC=C2)C2=C(C1)C=C1OCOC1=C2 SDPQMKFQURYHMV-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
241000976983 Anoxia Species 0.000 description 1
108010087765 Antipain Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
WYSYOQFANBUNSI-UHFFFAOYSA-N C(C)C1=NN=C(C2=C(C1)C=C1C(=C2)OCO1)C1=CC=C(C=C1)[N+](=O)[O-] Chemical compound C(C)C1=NN=C(C2=C(C1)C=C1C(=C2)OCO1)C1=CC=C(C=C1)[N+](=O)[O-] WYSYOQFANBUNSI-UHFFFAOYSA-N 0.000 description 1
PMILXCRDBHEPNU-UHFFFAOYSA-N C(C)OC(=O)C1N(N=CC=2C(C1)=C(C=C1C2OCO1)C1=CC=C(C=C1)[N+](=O)[O-])C Chemical compound C(C)OC(=O)C1N(N=CC=2C(C1)=C(C=C1C2OCO1)C1=CC=C(C=C1)[N+](=O)[O-])C PMILXCRDBHEPNU-UHFFFAOYSA-N 0.000 description 1
BZTDTSHGVBUZAG-UHFFFAOYSA-N C12=CC=3OCOC=3C=C2C=C(C)N(C(=O)OC)N=C1C1=CC=C([N+]([O-])=O)C=C1 Chemical compound C12=CC=3OCOC=3C=C2C=C(C)N(C(=O)OC)N=C1C1=CC=C([N+]([O-])=O)C=C1 BZTDTSHGVBUZAG-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010009346 Clonus Diseases 0.000 description 1
229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
SPFKJHFWDBRCKV-UHFFFAOYSA-N N=1N(C(C)=O)C(CC)=CC2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 Chemical compound N=1N(C(C)=O)C(CC)=CC2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 SPFKJHFWDBRCKV-UHFFFAOYSA-N 0.000 description 1
DLOLNUDILYRAJO-UHFFFAOYSA-N N=1N(C(C)=O)C(CC)=CC2=CC=3OCOC=3C=C2C=1C1=CC=C([N+]([O-])=O)C=C1 Chemical compound N=1N(C(C)=O)C(CC)=CC2=CC=3OCOC=3C=C2C=1C1=CC=C([N+]([O-])=O)C=C1 DLOLNUDILYRAJO-UHFFFAOYSA-N 0.000 description 1
206010060860 Neurological symptom Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
238000006350 Schiemann fluorination reaction Methods 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
208000010513 Stupor Diseases 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
206010043994 Tonic convulsion Diseases 0.000 description 1
208000030886 Traumatic Brain injury Diseases 0.000 description 1
201000004810 Vascular dementia Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
230000007953 anoxia Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
150000008107 benzenesulfonic acids Chemical class 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000001728 carbonyl compounds Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
JPBGLQJDCUZXEF-UHFFFAOYSA-N chromenylium Chemical class [O+]1=CC=CC2=CC=CC=C21 JPBGLQJDCUZXEF-UHFFFAOYSA-N 0.000 description 1
CHZWRIFDYXSVOD-UHFFFAOYSA-M chromenylium;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.[O+]1=CC=CC2=CC=CC=C21 CHZWRIFDYXSVOD-UHFFFAOYSA-M 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
230000002566 clonic effect Effects 0.000 description 1
229960003920 ***e Drugs 0.000 description 1
OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
230000001934 delay Effects 0.000 description 1
150000001989 diazonium salts Chemical class 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 1
125000005594 diketone group Chemical group 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
238000007654 immersion Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910052987 metal hydride Inorganic materials 0.000 description 1
150000004681 metal hydrides Chemical class 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
150000002826 nitrites Chemical class 0.000 description 1
LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
229910000510 noble metal Inorganic materials 0.000 description 1
230000006959 non-competitive inhibition Effects 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
210000004279 orbit Anatomy 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
WVIICGIFSIBFOG-UHFFFAOYSA-N pyrylium Chemical class C1=CC=[O+]C=C1 WVIICGIFSIBFOG-UHFFFAOYSA-N 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000001119 stannous chloride Substances 0.000 description 1
235000011150 stannous chloride Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000010936 titanium Substances 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Toxicology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO19970435A 1994-08-01 1997-01-31 Nye, 3-substituerte 3H-2,3-benzodiazepinderivater, fremstilling av dem og anvendelse av dem for fremstilling av legemidler NO319151B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE4428835A DE4428835A1 (de)	1994-08-01	1994-08-01	Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
PCT/DE1995/001029 WO1996004283A1 (de)	1994-08-01	1995-07-28	Neue 3-substituierte 3h-2,3-benzodiazepinderivate, deren herstellung und verwendung als arzneimittel

Publications (3)

Publication Number	Publication Date
NO970435L NO970435L (no)	1997-01-31
NO970435D0 NO970435D0 (no)	1997-01-31
NO319151B1 true NO319151B1 (no)	2005-06-27

Family

ID=6525693

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19970435A NO319151B1 (no)	1994-08-01	1997-01-31	Nye, 3-substituerte 3H-2,3-benzodiazepinderivater, fremstilling av dem og anvendelse av dem for fremstilling av legemidler

Country Status (21)

Country	Link
US (1)	US5756495A (fi)
EP (1)	EP0775143B1 (fi)
JP (1)	JPH10504543A (fi)
KR (1)	KR100386709B1 (fi)
CN (1)	CN1048728C (fi)
AT (1)	ATE223415T1 (fi)
AU (1)	AU693241B2 (fi)
CA (1)	CA2195747C (fi)
CZ (1)	CZ291276B6 (fi)
DE (2)	DE4428835A1 (fi)
DK (1)	DK0775143T3 (fi)
ES (1)	ES2181787T3 (fi)
FI (1)	FI113177B (fi)
HU (1)	HU225500B1 (fi)
MX (1)	MX9700813A (fi)
NO (1)	NO319151B1 (fi)
NZ (1)	NZ290777A (fi)
PT (1)	PT775143E (fi)
RU (1)	RU2146678C1 (fi)
SK (1)	SK284103B6 (fi)
WO (1)	WO1996004283A1 (fi)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP9701325A1 (hu)	1997-07-31	2000-08-28	Gyógyszerkutató Intézet Kft.	Új 2,3-benzodiazepin-származékok
JP2001512731A (ja) *	1997-08-12	2001-08-28	エギシュヂョヂセルヂャールエルテー	ＡＭＰＡ／Ｋａｉｎａｔｅ受容体阻害剤としての１，３−ジオキソロ／４，５−Ｈ／２，３／ベンゾジアゼピン誘導体
UA67749C2 (uk)	1997-08-12	2004-07-15	Егіш Дьйодьсердьяр Рт.	Похідна 8-заміщеного-9н-1,3-діоксол/4,5-h//2,3/бензодіазепіну з властивостями амра/каїнатного антагоніста, спосіб одержання похідних, фармацевтична композиція (варіанти), спосіб її одержання та спосіб лікування
HU227128B1 (en) *	1999-07-07	2010-07-28	Egyt Gyogyszervegyeszeti Gyar	New 2,3-benzodiazepine derivatives
NO320473B1 (no) *	2002-09-09	2005-12-12	Norsk Hydro As	Anordning ved separator for separasjon av flerfasefluid.
US6858605B2 (en)	2003-02-04	2005-02-22	Ivax Drug Research Institute, Ltd.	Substituted 2,3-benzodiazepine derivatives
GB0405034D0 (en) *	2004-03-05	2004-04-07	Novartis Ag	Organic compounds
AU2006232517A1 (en) *	2005-04-04	2006-10-12	Eisai R&D Management Co., Ltd.	Dihydropyridine compounds and compositions for headaches
DK2295049T3 (en) *	2005-09-09	2015-02-23	Novartis Ag	Treatment of autoimmune diseases
WO2015121268A1 (de) *	2014-02-14	2015-08-20	Bayer Pharma Aktiengesellschaft	1-phenyl-3h-2,3-benzodiazepine und ihre verwendung als bromodomänen-inhibitoren

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU219778B (hu) *	1990-12-21	2001-07-30	Gyógyszerkutató Intézet Közös Vállalat	Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények

1994
- 1994-08-01 DE DE4428835A patent/DE4428835A1/de not_active Withdrawn
1995
- 1995-07-28 DK DK95927636T patent/DK0775143T3/da active
- 1995-07-28 PT PT95927636T patent/PT775143E/pt unknown
- 1995-07-28 WO PCT/DE1995/001029 patent/WO1996004283A1/de active IP Right Grant
- 1995-07-28 DE DE59510364T patent/DE59510364D1/de not_active Expired - Fee Related
- 1995-07-28 CZ CZ1997159A patent/CZ291276B6/cs not_active IP Right Cessation
- 1995-07-28 ES ES95927636T patent/ES2181787T3/es not_active Expired - Lifetime
- 1995-07-28 HU HU9700320A patent/HU225500B1/hu unknown
- 1995-07-28 CN CN95194402A patent/CN1048728C/zh not_active Expired - Fee Related
- 1995-07-28 AT AT95927636T patent/ATE223415T1/de not_active IP Right Cessation
- 1995-07-28 NZ NZ290777A patent/NZ290777A/en unknown
- 1995-07-28 CA CA002195747A patent/CA2195747C/en not_active Expired - Fee Related
- 1995-07-28 MX MX9700813A patent/MX9700813A/es unknown
- 1995-07-28 SK SK135-97A patent/SK284103B6/sk unknown
- 1995-07-28 JP JP8506095A patent/JPH10504543A/ja not_active Ceased
- 1995-07-28 AU AU31609/95A patent/AU693241B2/en not_active Ceased
- 1995-07-28 US US08/776,536 patent/US5756495A/en not_active Expired - Fee Related
- 1995-07-28 EP EP95927636A patent/EP0775143B1/de not_active Expired - Lifetime
- 1995-07-28 RU RU97103140A patent/RU2146678C1/ru not_active IP Right Cessation
- 1995-07-28 KR KR1019970700650A patent/KR100386709B1/ko not_active IP Right Cessation
1997
- 1997-01-31 NO NO19970435A patent/NO319151B1/no unknown
- 1997-01-31 FI FI970434A patent/FI113177B/fi active

Also Published As

Publication number	Publication date
MX9700813A (es)	1997-05-31
DE59510364D1 (de)	2002-10-10
JPH10504543A (ja)	1998-05-06
NO970435L (no)	1997-01-31
CN1155285A (zh)	1997-07-23
CA2195747C (en)	2006-01-24
WO1996004283A1 (de)	1996-02-15
FI970434A0 (fi)	1997-01-31
KR100386709B1 (ko)	2003-08-19
FI113177B (fi)	2004-03-15
NO970435D0 (no)	1997-01-31
PT775143E (pt)	2003-01-31
US5756495A (en)	1998-05-26
CA2195747A1 (en)	1996-02-15
CN1048728C (zh)	2000-01-26
HUT76801A (en)	1997-11-28
DK0775143T3 (da)	2002-12-02
HU225500B1 (en)	2007-01-29
CZ15997A3 (en)	1997-06-11
CZ291276B6 (cs)	2003-01-15
ATE223415T1 (de)	2002-09-15
FI970434A (fi)	1997-01-31
AU3160995A (en)	1996-03-04
EP0775143B1 (de)	2002-09-04
RU2146678C1 (ru)	2000-03-20
EP0775143A1 (de)	1997-05-28
ES2181787T3 (es)	2003-03-01
SK13597A3 (en)	1997-07-09
AU693241B2 (en)	1998-06-25
NZ290777A (en)	1998-07-28
DE4428835A1 (de)	1996-02-08
SK284103B6 (sk)	2004-09-08

Publication	Publication Date	Title
HU197002B (en)	1989-02-28	Process for producing glutarimide derivatives
JPWO2002074746A1 (ja)	2004-07-08	ベンゾアゼピン誘導体
US6759405B2 (en)	2004-07-06	Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
RU1779251C (ru)	1992-11-30	Способ получени 1-(4-аминофенил)-4-метил-7,8-метилендиокси-3,4-дигидро-5Н-2,3-бензодиазепина или его кислотно-аддитивных солей
SK129394A3 (en)	1995-05-10	1-piperazino-1,2-dihydroindene derivatives, pharmaceutical agents with their contents and their use
US6200970B1 (en)	2001-03-13	2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors
NO319151B1 (no)	2005-06-27	Nye, 3-substituerte 3H-2,3-benzodiazepinderivater, fremstilling av dem og anvendelse av dem for fremstilling av legemidler
DE69820989T2 (de)	2004-12-09	Tricyclische benz[e]isoindole und benz[h]isochinoline
EA000471B1 (ru)	1999-08-26	Производные 2,3-бензодиазепина
US6075018A (en)	2000-06-13	1-[2-(substituted vinyl)]-3,4-dihydro-4-dihydro-5H-2,3-benzodiazepine derivatives
US6482819B1 (en)	2002-11-19	2,3-benzodiazepine derivatives
EA003991B1 (ru)	2003-12-25	Производные 2-аминопиридинов, способ ингибирования синтазы оксида азота, фармацевтические композиции и способы лечения
DE19617863A1 (de)	1997-10-30	Phthalazinderivate, deren Herstellung und Verwendung als Arzneimittel
JPH11130759A (ja)	1999-05-18	新規な二置換ｔｒａｎｓ−３，４，４ａ，５，６，１０ｂ−ヘキサヒドロ−２Ｈ−ナフト〔１，２−ｂ〕−１，４−オキサジン、それらの製造方法及びそれらを含有する医薬組成物
BG66199B1 (bg)	2012-01-31	2,3-беhзодиазепинови производни и фармацевтични състави, които ги съдържат като активен компонент
AU2004261491B2 (en)	2009-12-17	8-chloro-2,3-benzodiazepine derivatives
CA2169115C (en)	2000-07-25	1-¬2-(substituted vinyl)\|-5h-2,3-benzodiazepine derivatives
JPS6043068B2 (ja)	1985-09-26	アゼピノ〔１，２，３−１ｍ〕−β−カルボリン誘導体及びその製法
AU720745B2 (en)	2000-06-08	Novel 2,3-benzodiazepine derivatives
EP0726257A1 (en)	1996-08-14	1-(Hetero)Arylvinyl-5H-2,3-benzodiazepine derivatives useful for the treatment of central nervous system disorders, and benzopyrylium intermediates for their preparation